Cibus, Inc. (CBUS)
| Market Cap | 71.59M |
| Revenue (ttm) | 4.85M |
| Net Income (ttm) | -275.33M |
| Shares Out | 54.24M |
| EPS (ttm) | -8.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 183,111 |
| Open | 1.390 |
| Previous Close | 1.370 |
| Day's Range | 1.320 - 1.410 |
| 52-Week Range | 1.220 - 7.980 |
| Beta | 1.76 |
| Analysts | Strong Buy |
| Price Target | 22.00 (+1,566.67%) |
| Earnings Date | Aug 14, 2025 |
About CBUS
Cibus, Inc., an agricultural biotechnology company, develops and licenses gene edited plant traits using gene editing technologies to enhance farming productivity or produce renewable low carbon plant products. It focuses on trait productivity in the productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients, which enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The ... [Read more]
Financial Performance
In 2024, Cibus's revenue was $4.26 million, an increase of 134.56% compared to the previous year's $1.82 million. Losses were -$251.39 million, -6.07% less than in 2023.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for CBUS stock is "Strong Buy." The 12-month stock price target is $22.0, which is an increase of 1,566.67% from the latest price.
News
Cibus, Inc. (CBUS) Q2 2025 Earnings Call Transcript
Cibus, Inc. (NASDAQ:CBUS) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Cornelis Broos - Interim Chief Financial Officer Gregory F. Gocal - Co-Founder, Chief Scient...
Cibus Reports Second Quarter Financial Results and Provides Year-to-Date Business Update for 2025
Streamlining operational focus on Rice herbicide tolerance traits and partner-funded and/or supported programs, expected to reduce annual cash usage to approximately $30 million by 2026
Cibus to Report Second Quarter 2025 Financial Results on August 14, 2025 After the Market Close and Host Conference Call
SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the c...
The U.S. Food and Drug Administration Completes Review of Cibus' Altered Lignin Alfalfa Developed in Partnership with S&W Seed Company for use in Livestock Feed
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant traits to seed companies, announced ...
Cibus and John Innes Centre Announce Ongoing Collaboration with Potential to Revolutionize Fertilizer Use in Farming
Researchers at the John Innes Centre (JIC) have discovered a genetic mutation with the potential to enhance nutrient uptake and reduce the need for artificial fertilizers Cibus and JIC have agreed on ...
Cibus, Inc. Announces Closing of $27.5 Million Public Offering
SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to deve...
USDA Designates Cibus' Herbicide Tolerance Canola Trait HT2 as Not Regulated Under USDA's Biotechnology Regulations
This action follows the USDA's recent designation of Cibus' disease resistance traits in Canola as not regulated, continuing Cibus' product development momentum in the globally important Canola crop T...
Cibus, Inc. Announces Pricing of $27.5 Million Public Offering
SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to deve...
Cibus, Inc. Announces Proposed Public Offering
SAN DIEGO, June 04, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to deve...
Cibus Provides Webcast of BofA Securities AgTech Virtual Conference Fireside Chat
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant tr...
Cibus to Participate in Alliance Global Partner's Annual Virtual Healthcare Company Showcase
SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant tr...
Cibus, Inc. (CBUS) Q1 2025 Earnings Call Transcript
Cibus, Inc. (NASDAQ:CBUS) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Carlo Broos - Interim CFO Peter Beetham - Co-Founder, Interim CEO, President, COO & Director Gre...
Cibus Reports First Quarter Financial Results and Provides Year-to-Date Business Update for 2025
Rice business momentum builds with Cibus' first stacked gene edited herbicide tolerance traits, which the Company believes is an industry first; On track for 2027 targeted commercial launch of HT1 and...
Ecuador Approves Cibus Herbicide Tolerance Traits as Equivalent to Conventional Breeding
Designation confirms conventional regulation of Cibus herbicide tolerance traits in Rice in Ecuador paving the way for further product development and eventual commercialization in a key Rice growing ...
Cibus to Report First Quarter 2025 Financial Results on May 8, 2025 After the Market Close and Host Conference Call
SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or speci...
USDA-APHIS Designates Additional Cibus' Disease Resistance Trait Products as Not Regulated
Designation confirms conventional regulation of Cibus traits in the U.S. as modernized regulatory policy for precision gene editing breeding technologies continues to advance globally Designation conf...
Cibus, Inc. (CBUS) Q4 2024 Earnings Call Transcript
Cibus, Inc. (NASDAQ:CBUS) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Carlo Broos - Interim Chief Financial Officer Peter Beetham - Co-Founder, President and COO, ...
Cibus Reports Fourth Quarter Financial Results and Provides Business Update
A major milestone on March 14th 2025 advanced the EU Trilogue discussions aimed to complete the final text of the New Genomic Techniques (NGTs) or gene editing legislation for the EU; California Rice ...
Cibus Welcomes the European Union's Progress as Legislation for New Genomic Techniques to Boost Innovation and Sustainability Moves Forward
Legislation aims to adapt EU law to reflect scientific and technological progress, enabling the products of New Genomic Techniques (NGTs), such as gene editing, to contribute to more sustainable agric...
Cibus to Report Fourth Quarter 2024 Financial Results on March 20, 2025 After the Market Close and Host Conference Call
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or speci...
Cibus' Achieves Another Milestone for a Durable White Mold (Sclerotinia) Resistance Trait in Canola
Initial bioassay data for Cibus' third mode of action for white mold (Sclerotinia) resistance trait in canola shows promising results in controlled environment assessment
Cibus Announces Leadership Change and CEO Succession Plan
SAN DIEGO, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies ...
Cibus Announces Important Update to Rice Gene Editing Conversion Rates
SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies ...
Cibus to Participate in the Sidoti Micro Cap Conference
SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant t...
Cibus, Inc. Announces $22.6 Million Registered Direct Offering Priced Above Nasdaq's Minimum Price in Accordance with Nasdaq Rules
SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to deve...